H1 23 results: revenue +44%YoY
For the six months to 31 October 2022 Kromek reported revenue of £6.8m, +44.1% YoY, gross profit of £2.74m, +24.3%YoY, a 40.4% margin compared to 46.8% a year earlier, and an (adj.) EBITDA loss of £(2.666)m attributable to a combination of inventory build – offsetting components supply chain factors – cost inflation and a £0.5m $:£ currency move. The loss before tax (reported) was £(5.671)m. As of 31 October 2022 the cash position was £0.96m, with net debt at £8.30m. Kromek reports that by 23 January the cash position had improved to £1.3m.Kromek reported an order book with 84% of revenue reported to be either contracted or already shipped, 5% under negotiation and 2% arising from repeat business; leaving 9% to be filled by new opportunities, underpinning confidence in the full year outlook.
The Advanced Imaging segment has benefitted from significant contracts and customer engagement in key target areas, notably SPECT (single photon emission computed tomography) and CT (computed tomography). Continued geopolitical uncertainty underpins demand for Kromek’s range of D3 and D5 radiation detectors in the CBRN segment, evident in the major post period-end £4.9m UK government contract for development of biological threat-detection systems.
Our FY23 revenue outlook remains unchanged at £18.0m +49%YoY (E). For FY24 we anticipate healthy revenue growth of 16.7%YoY, and an (adj.) EBITDA profit of just under £1.0m. We also maintain our Fair Value at 26p/share.
Kromek Group is a developer of radiation detectors based on cadmium zinc telluride, providing detection and characterization capabilities within the medical imaging, nuclear detection and security screening markets. Co. designs, develops and produces x-ray and gamma-ray imaging and radiation detection products.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.